# Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

> **NCT03632291** · PHASE1 · COMPLETED · sponsor: **United BioPharma** · enrollment: 15 (actual)

## Conditions studied

- Urticaria Chronic

## Interventions

- **BIOLOGICAL:** UB-221

## Key facts

- **NCT ID:** NCT03632291
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2021-01-19
- **Final completion:** 2021-01-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03632291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03632291, "Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03632291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*